中国药业2012，Vol.21Issue(5)：65-66,2.
利伐沙班预防髋关节置换术后深静脉血栓形成60例
Clinical Application of Rivaroxaban in Preventing Deep Vein Thrombosis after Hip Replacement in 60 Cases
钱建敏 1舒建国1
作者信息
- 1. 浙江省嵊州市中医院骨科,浙江绍兴,312400
- 折叠
摘要
Abstract
Objective To study the clinical efficacy of rivaroxaban in the prevention of deep vein thrombosis after hip replacement. Methods A hundred and twenty patients with hip replacement surgery in our hospital from January 2009 to January 2011 were selected and randomly divided into two groups, the rivaroxaban and the low molecular weight heparin group, 60 cases in each group. The rivaroxaban group was given oral rivaroxaban 10 mg at 6 h after surgery, once daily for 14 successive 14 d, while the low molecular weight heparin group was given low molecular weight heparin 40 mg by subcutaneous injection within 24 h after operation, once daily for successive 14 d. After 14 d treatment, the deep veins of lower extremities in the two groups were performed the color Doppler ultrasound examination. Then, the deep vein thrombosis and the incidence of postoperative deep vein thrombosis were compared between the two groups. Results Nine cases in the low molecular weight heparin group had deep vein thrombosis with the occurrence rate of 15. 00%. Two cases in the rivaroxaban group had deep venous thrombosis with the occurrence rate of 3. 33%. Two groups had statistically significant difference (P< 0.05). No adverse events occurred in the rivaroxaban group. Conclusion Rivaroxaban can effectively prevent deep vein thrombosis after hip replacement surgery, which has good security and is worthy of being popularized in clinic.关键词
利伐沙班/低分子肝素/髋关节置换术/预防/深静脉血栓Key words
rivaroxaban/ low molecular weight heparin/ hip replacement/ prevention/ deep vein thrombosis分类
医药卫生引用本文复制引用
钱建敏,舒建国..利伐沙班预防髋关节置换术后深静脉血栓形成60例[J].中国药业,2012,21(5):65-66,2.
